Is omega-3 ‘so 2008’?

Article

 

San Diego-“The title of this course is appropriate,” said Kimberly Reed, OD, at the opening of her Ocular Nutrition Society presentation, Controversies in Nutrition. The content of Dr. Reed’s course was especially controversial in light of the AREDS 2 report that was just recently released. But the controversy didn’t end there.

Dr. Reed began her lecture with a criticism of the overly dramatic publicity resulting from a piece on omega-3 published in the September 2012 Journal of the American Medical Association (JAMA). The summaries of this research said that omega-3s are not associated with lower risk of all-cause mortality cardiac threat or stroke. However, what’s overlooked is that this was a meta-analysis, she said. It looked at 20 different studies. In other words, these are not all the same type of patient. There was a lot of variation. Too much, she said. Also, the omega dosage range was huge, varying from 0.027 g to 6 g per day. Likewise, age varied greatly, as did the end point, or points-in some studies it was death, in others it was stroke. In fact, a lot of the patients were extremely sick.

“This type of meta-analysis is of little value,” said Dr. Reed, who also questioned what types of omega-3 were used in the JAMA study. Dr. Reed pointed out that risk of sudden cardiac death was reduced by as much as 90% with omega-3s according to another study that was published in the New England Journal of Medicine. Likewise, Dr. Reed also cited a study that found a 27% reduced risk. And, she added, coronary heart disease, specifically, was reduced by 50% in a study by Mozaffarian. This long-term study watched people over 16 years, she noted. “And omega-3s added an average 2 years of life.”

“But what about AREDS 2?” she asked the audience. It used 1000 mg total omega-3 (350 DHA 650 EHA) and it didn’t have much affect in preventing progression from moderate to advanced disease. The Rotterdam study showed a 35% reduction in risk with dietary intake, she noted.

So why did this happen in AREDS 2? Is 350 DHA 650 EHA not enough? Stuart Richer, OD, PhD, nutrition science lecturer who was also presenting at the meeting, said he now recommends double and triple strength fish oils.

Regarding dose, Dr. Reed said, “for most patients 2000 of omega-3 EPA/DHA is required to surpass the 8% Red Blood Cell saturation found to be beneficial in reducing cardiovascular mortality.”ODT

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.